peptides growth hormone: Frequently asked questions

First verify peptide purity and reconstitution protocol. Degraded or improperly stored peptides lose bioactivity. If purity is confirmed, the issue is likely receptor saturation or timing. GHRH analogs must be administered when somatostatin levels are low. Taking them during a somatostatin pulse (which occurs naturally every 3–5 hours) blocks their effect entirely. Ghrelin mimetics have a narrower timing window and should be administered on an empty stomach at least 2 hours after food intake, when ghrelin's natural metabolic signaling is active.

Ipamorelin is the only peptide that maintains >85% potency beyond 16 weeks of continuous daily administration. GHRP-2 shows moderate attenuation (15–20% reduction) by week 12, and hexarelin becomes nearly inactive by week 4. CJC-1295 with DAC doesn't desensitize but suppresses endogenous pulsatility for the entire duration. If the protocol exceeds 12 weeks and endogenous GH dynamics must remain intact, ipamorelin is the only viable option.

Hexarelin produces the highest-amplitude GH release among all peptide secretagogues. 15–25 ng/mL peaks at 2 mcg/kg dosing. However, this comes at the cost of rapid receptor desensitization, which limits protocol duration to 2–4 weeks. If the research question involves measuring peak GH capacity or downstream signaling during supra-physiological GH exposure, hexarelin is the appropriate tool. But only in short-term studies where receptor attenuation won't confound the data.

Avoid MK-677. Its 24-hour ghrelin receptor occupancy increases fasting glucose by 8-12 mg/dL in insulin-resistant individuals, likely through glucagon stimulation and hepatic glucose output. Ipamorelin or hexarelin paired with metformin or berberine represents a safer approach. Both compounds produce GH release without sustained ghrelin signaling, and metformin counteracts the modest insulin resistance that high-dose GH can induce. A 2021 study in Diabetes Care found that co-administration of 500 mg metformin with ipamorelin protocols prevented the 6-8% increase in fasting glucose observed with MK-677 alone.

Use ipamorelin or CJC-1295 without DAC. Both produce discrete pulses that preserve the body's endogenous secretory pattern. Ipamorelin peaks within 20 minutes and clears within 90 minutes, while CJC-1295 (no DAC) extends the pulse duration slightly without suppressing inter-pulse intervals. CJC-1295 with DAC is inappropriate for this scenario because its sustained albumin-bound presence flattens circadian variation entirely, suppressing the nocturnal GH surge that occurs during slow-wave sleep.

GH-to-IGF-1 conversion occurs in the liver and is modulated by nutritional status, thyroid hormone, and insulin sensitivity. Inadequate protein intake (below 1.6 g/kg body weight), hypothyroidism, or insulin resistance can blunt hepatic IGF-1 synthesis even when GH secretion is elevated. Verify thyroid function (TSH, free T3) and ensure caloric sufficiency. GH is catabolic in energy deficit states, limiting anabolic IGF-1 production.

Increase GHRP dose incrementally (from 100 mcg to 200 mcg per injection) and verify injection timing is strictly on an empty stomach. Post-meal insulin blunts GH secretion. If IGF-1 remains flat after 8 weeks at higher dose, pituitary reserve may be insufficient, and direct IGF-1 supplementation (IGF-1 LR3) or pharmaceutical GH replacement should be considered. Low responders often have undiagnosed thyroid dysfunction or chronic sleep deprivation. Both suppress GH axis independent of peptide dose.

These are expected effects of elevated GH. Growth hormone increases sodium retention via the kidneys and stimulates extracellular fluid expansion. Reducing dosage from 25 mg to 12.5 mg daily typically alleviates symptoms while maintaining 60–70% of the IGF-1 increase. Joint discomfort usually resolves within 2–3 weeks as connective tissues adapt to increased collagen synthesis. If symptoms persist beyond 4 weeks, discontinue MK-677 and switch to injectable peptides with shorter half-lives.

Use the combination. CJC-1295 alone extends the duration of GHRH signaling but doesn't increase pulse amplitude. It raises baseline GH secretion modestly. Ipamorelin adds peak amplitude by triggering GH release through ghrelin receptors, which means the combined effect is both higher baseline and sharper pulses. Research protocols using both together show 2–3× the IGF-1 increase compared to either peptide alone.

This indicates receptor desensitisation, most common with hexarelin and GHRP-2. Implement a washout period of 7–14 days to allow GHS-R1a receptor resensitisation, then resume at the same dose. Alternatively, rotate between GHS-R1a agonists and GHRH analogs every 4–6 weeks. The distinct receptor pathways prevent cross-desensitisation. Research models using cyclical dosing (5 days on, 2 days off) show sustained response over 12+ weeks without significant attenuation.

Yes, but expect a 4–6 week transition period. Stop synthetic HGH administration and wait 2–3 weeks before starting peptides. This allows the negative feedback suppression to resolve and the pituitary to regain GHRH sensitivity. During this washout period, you'll experience temporarily low GH levels as your natural production restarts. Once peptides are introduced, GH pulses should return to normal amplitude within 2–4 weeks, though full restoration of pre-HGH dynamics can take up to 12 weeks depending on how long synthetic HGH was used.

Discard the vial immediately. Cloudiness or visible particulates indicate either microbial contamination or peptide aggregation, both of which render the solution unsafe and ineffective. Properly reconstituted peptides should be crystal clear with no visible debris. Contaminated peptides can cause injection-site infections or systemic inflammatory responses. This is why aseptic technique during reconstitution is non-negotiable.

Stack hexarelin (100 mcg) with MOD-GRF 1-29 (100 mcg) administered 15 minutes before the target measurement window. This combination exploits full receptor synergy without the prolonged occupancy of long-acting analogs. Research from the Journal of Clinical Endocrinology documented GH peaks exceeding 50 ng/mL within 20-30 minutes of co-administration, a response magnitude unattainable with rhGH injections. This protocol is used in provocative GH testing and research models requiring maximal acute secretion rather than sustained elevation.

Use CJC-1295 with DAC as the base compound. Its 6-8 day half-life allows twice-weekly dosing while maintaining IGF-1 elevation throughout the study period. Research conducted at the University of Virginia demonstrated that 60 mcg/kg CJC-1295 administered every 7 days produced sustained IGF-1 increases of 40-60% above baseline for the entire inter-dose interval. This eliminates the compliance challenges of daily peptide reconstitution and injection timing. The trade-off: you lose the ability to time doses around specific anabolic windows like post-exercise or sleep onset, which matters if the research protocol targets acute GH pulses rather than chronic IGF-1 elevation.

Resume the protocol at the next scheduled time. Do not double-dose to 'catch up.' GH release follows a natural pulsatile rhythm; trying to compensate with higher doses disrupts receptor signalling and increases cortisol elevation without improving IGF-1 outcome. Missing one or two doses per week has minimal impact on cumulative IGF-1 levels as long as you maintain consistency on other days.

First, verify peptide reconstitution and storage. Improperly stored peptides (above 8°C for more than 48 hours) lose potency irreversibly. Second, confirm injection timing. Administering peptides immediately after meals blunts GH release due to elevated glucose and insulin. Third, check dosage accuracy using an insulin syringe with 0.01 mL graduations. If all three are correct and IGF-1 remains unchanged, the issue is likely pituitary insufficiency rather than hypothalamic. Meaning ghrelin agonists may be ineffective, and GHRH analogues are addressing a problem downstream of where the failure actually occurs.

Discard the vial. Reconstituted peptides lose 30–50% of receptor binding affinity after 8 hours at 20–25°C due to methionine oxidation and aggregation. Refrigeration at 2–8°C stabilises peptide structure for 28 days post-reconstitution, but any temperature excursion above 8°C accelerates degradation exponentially. There is no visual indicator of potency loss. The solution remains clear even when biologically inactive.

Peptides restore physiological GH dynamics. They don't produce pharmacological supraphysiological levels the way synthetic HGH does. If your goal requires GH levels above the normal physiological range (bodybuilding, extreme performance enhancement), peptides won't achieve that. They're designed to restore deficiency to normal, not elevate normal to supranormal. Synthetic HGH produces faster visible changes because it floods receptors beyond natural capacity, but that same mechanism causes the long-term suppression peptides avoid.

You'll still get a GH pulse, but it will be 40–50% weaker and shorter in duration compared to sequential dosing. The GHRH and GHRP pathways work synergistically when staggered. Simultaneous injection doesn't allow the GHRH receptor priming phase to complete before the ghrelin mimetic arrives. If this happens once, resume sequential protocol the next day; one mistimed dose won't derail long-term IGF-1 gains.

Switch from GHRP-6 or GHRP-2 to ipamorelin, which shows negligible ghrelin pathway activation in controlled trials. If combination therapy is required, pair ipamorelin with modified GRF 1-29 (a GHRH analogue without appetite effects) rather than compounds that activate orexigenic pathways. Caloric intake logs are insufficient to control for ghrelin-driven hunger. The endocrine signal overrides voluntary restriction in most subjects.